Montanide ISA51

flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer

Vaccine Therapy in Treating Patients With Metastatic Cancer

Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye

Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma

Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma

Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides

Vaccination With Tetanus and KLH to Assess Immune Responses.

Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy

Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides

Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma

Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma

Evaluation of the Effects of Local Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes: MEL38